Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 3/20 | 0.33 |
| ▸ | JAK2 | O60674 | 4/20 | 0.33 |
| ▸ | JAK3 | P52333 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL219272 | 1.00 | APLNR (0.33) | APLNRJAK2JAK3 | |
| SCHEMBL12067749 | 1.00 | APLNR (0.33) | APLNRJAK2JAK3 | |
| Hydrochloric Acid SCHEMBL1693931 | 0.98 | APLNR (0.33) | APLNRJAK2JAK3 | |
| Hydrochloric Acid SCHEMBL218361 | 0.98 | APLNR (0.33) | APLNRJAK2JAK3 | |
| Hydrochloric Acid SCHEMBL219928 | 0.98 | APLNR (0.33) | APLNRJAK2JAK3 | |
| SCHEMBL2625465 | 0.79 | PTGS1 (0.36) | APLNRJAK2JAK3 | |
| SCHEMBL13943922 | 0.77 | APLNR (0.54) | APLNR | |
| SCHEMBL14677407 | 0.77 | APLNR (0.54) | APLNR | |
| SCHEMBL23230046 | 0.75 | CHRNA7 (0.33) | APLNR | |
| SCHEMBL14846893 | 0.75 | ADRB2 (0.41) | APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092778-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS AND METHODS | PYRAMID BIOSCIENCES INC (US) | 2024-03-21 | — | — | US | disclosed |
| CN-116782883-A | Topical pharmaceutical compositions and methods | 金字塔生物科技公司 | 2023-09-19 | — | — | CN | disclosed |
| WO-2022144758-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS AND METHODS | PYRAMID BIOSCIENCES, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| WO-2022144758-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS AND METHODS | PYRAMID BIOSCIENCES, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| US-10844044-B2 | WDR5 inhibitors and modulators | VANDERBILT UNIVERSITY (US) | 2020-11-24 | — | — | US | disclosed |
| US-10759793-B2 | 2-(pyrazolopyridin-3-yl)pyrimidine derivatives as JAK inhibitors | ALMIRALL, S.A. (ES) | 2020-09-01 | — | — | US | disclosed |
| US-20200102288-A1 | WDR5 INHIBITORS AND MODULATORS | VANDERBILT UNIVERSITY | 2020-04-02 | — | — | US | disclosed |
| US-20180162856-A1 | 2-(PYRAZOLOPYRIDIN-3-YL)PYRIMIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2018-06-14 | — | — | US | disclosed |
| EP-3307272-A1 | 2-(PYRAZOLOPYRIDIN-3-YL)PYRIMIDINE DERIVATIVES AS JAK INHIBITORS | Almirall, S.A. (ES) | 2018-04-18 | — | — | EP | disclosed |
| WO-2017220431-A1 | FUSED PYRAZOLE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2017-12-28 | — | — | WO | disclosed |
| US-20110183954-A1 | TRICYCLIC 2,4-DIAMINO-L,3,5-TRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AND MYELOPROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-07-28 | — | — | US | disclosed |
| US-20110183954-A1 | TRICYCLIC 2,4-DIAMINO-L,3,5-TRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AND MYELOPROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-07-28 | — | — | US | disclosed |
| US-20100160325-A1 | 4-(3-AMINOPYRAZOLE) PYRIMIDINE DERIVATIVES FOR USE AS TYROSINE KINASE INHIBITORS IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2010-06-24 | — | — | US | disclosed |
| WO-2010038060-A1 | HETEROCYCLIC JAK KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
| WO-2009150462-A1 | TRICYCLIC 2,4-DIAMIN0-L,3,5-TRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AND MYELOPROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009016410-A2 | CHEMICAL COMPOUNDS 831 | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | WO | disclosed |
| US-20080287475-A1 | 4-(3-Aminopyrazole) Pyrimidine Derivatives for Use as Tyrosine Kinase Inhibitors in the Treatment of Cancer | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| EP-1945631-A1 | 4- (3-AMINOPYRAZOLE) PYRIMIDINE DERIVATIVES FOR USE AS TYROSINE KINASE INHIBITORS IN THE TREATMENT OF CANCER | AstraZeneca AB (SE) | 2008-07-23 | — | — | EP | disclosed |
| US-20080139561-A1 | e.g. 6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino) nicotinonitrile; tropomyosin-related kinases (Trk's) inhibitor; anticarcinogenic agent; hormone related cancer, leukemia; antiinflammatory agent; arthritis, restenosis; autoimmune diseases | ASTRAZENECA AB (SE) | 2008-06-12 | — | — | US | disclosed |
| WO-2007049041-A1 | 4- (3-AMINOPYRAZOLE) PYRIMIDINE DERIVATIVES FOR USE AS TYROSINE KINASE INHIBITORS IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139561-A1 | e.g. 6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino) nicotinonitrile; tropomyosin-related kinases (Trk's) inhibitor; anticarcinogenic agent; hormone related cancer, leukemia; antiinflammatory agent; arthritis, restenosis; autoimmune diseases | CNKSR1, LTK, MUSK | APLNR 920/4885JAK2 341/4885JAK3 697/4885 |
| US-20080287475-A1 | 4-(3-Aminopyrazole) Pyrimidine Derivatives for Use as Tyrosine Kinase Inhibitors in the Treatment of Cancer | ABL1, FLT3, ERBB2 | APLNR 2812/4885JAK2 35/4885JAK3 13/4885 |
| US-20200102288-A1 | WDR5 INHIBITORS AND MODULATORS | WDR5, WDR1, WDR3 | APLNR 3174/4885JAK2 3527/4885JAK3 3652/4885 |
| US-20100160325-A1 | 4-(3-AMINOPYRAZOLE) PYRIMIDINE DERIVATIVES FOR USE AS TYROSINE KINASE INHIBITORS IN THE TREATMENT OF CANCER | ABL1, FLT3, ERBB2 | APLNR 2812/4885JAK2 35/4885JAK3 13/4885 |
| US-20240092778-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS AND METHODS | CUTA, IL5, S100A8 | APLNR 3112/4885JAK2 716/4885JAK3 43/4885 |
| US-10844044-B2 | WDR5 inhibitors and modulators | WDR5, WDR1, WDR3 | APLNR 2972/4885JAK2 3427/4885JAK3 3605/4885 |
| US-20180162856-A1 | 2-(PYRAZOLOPYRIDIN-3-YL)PYRIMIDINE DERIVATIVES AS JAK INHIBITORS | JAK2, JAK3, JAK1 | APLNR 4233/4885JAK2 1/4885JAK3 2/4885 |
| US-10759793-B2 | 2-(pyrazolopyridin-3-yl)pyrimidine derivatives as JAK inhibitors | JAK2, JAK3, JAK1 | APLNR 4233/4885JAK2 1/4885JAK3 2/4885 |
| US-20110183954-A1 | TRICYCLIC 2,4-DIAMINO-L,3,5-TRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AND MYELOPROLIFERATIVE DISORDERS | THPO, MPL, MCL1 | APLNR 1494/4885JAK2 6/4885JAK3 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.